Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07605390 · ClinicalTrials.gov registry record · NA
RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care (RAPID-CKM)
A NA study, sponsored by Baylor Research Institute.
- Not yet
- Registry status
- NA
- Development phase
- 600
- Enrollment target
NCT07605390: Clinical Trial NA study, sponsored by Baylor Research Institute.
NCT07605390 is a NA study that has not yet begun recruiting, run by Baylor Research Institute. The registered enrollment target is 600 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07605390, a NA study, has not yet begun recruiting, sponsored by Baylor Research Institute.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 600 participants
- Enrollment target
Study Summary
The goal of this pragmatic randomized clinical trial is to determine whether an Epic-based clinician notification increases initiation of guideline-directed cardio-kidney-metabolic (CKM) therapies in adults with type 2 diabetes and confirmed albuminuria. The main question it aims to answer is: • Does an Epic clinician notification improve initiation of guideline-directed CKM therapies compared with usual care? Researchers will compare an Epic in-basket clinician notification strategy with usual care. In the intervention arm, the treating clinician will receive an Epic notification identifying confirmed albuminuria and potential eligibility for guideline-directed CKM therapies using existing electronic health record (EHR) data. Participants in the usual care arm will receive standard clinical care without notification.
Primary Outcome
Proportion of eligible participants newly prescribed one or more guideline-directed cardio-kidney-metabolic (CKM) therapies, including renin-angiotensin system inhibitors (RASi), sodium-glucose cotransporter-2 inhibitors (SGLT2i), non-steroidal mineralocorticoid receptor antagonists (ns-MRA), or glucagon-like peptide-1 receptor agonists (GLP-1RA) as assessed using electronic health record (EHR) data.
Interventions
- OTHER Usual Care
- OTHER Epic-Based Clinician Notification
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2026-08 |
| Est. Completion | 2028-01 |
| Phase | NA |
What is known before NCT07605390 opens enrollment
NCT07605390 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 2 interventions - of which Usual Care is the first listed.
NCT07605390 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07605390 about?
NCT07605390 is a clinical study titled "RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care (RAPID-CKM)". The goal of this pragmatic randomized clinical trial is to determine whether an Epic-based clinician notification increases initiation of guideline-directed cardio-kidney-metabolic (CKM) therapies in adults with type 2 diabetes and confirmed albuminuria. The main question it aims to answer is: • D...
What is the current status of trial NCT07605390?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 600 participants. The study started on 2026-08. Estimated completion is 2028-01.
What interventions are being tested in trial NCT07605390?
The interventions under investigation include: Usual Care (OTHER), Epic-Based Clinician Notification (OTHER).
Who is sponsoring clinical trial NCT07605390?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07605390's enrollment target sits among peer trials
600 162nd of 2000 higher than 1,827 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia